Life Sciences

News, research & analysis from the global Life Sciences and related industries.

March 8, 2018

Charles River Laboratories M&A Activity Analysis: A Differentiated Strategy Delivering Results

[vc_row][vc_column][vc_column_text] From its early days as one the first suppliers of animal models for research in 1947, Charles River Laboratories (CRL) has developed into a brand […]
February 22, 2018

Making Large-Scale Biomanufacturing More Efficient and Affordable: Have Novo Nordisk Foundation Made a Major Breakthrough?

[vc_row][vc_column][vc_column_text] The Novo Nordisk Foundation Centre for Biosustainability recently published an exciting finding that could herald the beginning of utilising bioproduction for the large-scale manufacture of […]
February 20, 2018

2018 Global Drug Development IPO Analysis: $10.24B Raised in Strongest Year on Record

[vc_row][vc_column][vc_column_text] The Drug Development IPO market enjoyed a strong year in 2018, with over $10.24B raised by 95 companies across 15 global exchanges. When compared to […]
January 30, 2018

Global Therapeutic IPO Review: $6.4B Raised as Bullish Investors Back Biologics & Gene Therapies Despite Slowed Growth in 2017

[vc_row][vc_column][vc_column_text]2017 saw a total of 73 Drug Development IPOs across 15 global exchanges, compared to 58 IPOs in 2016. In total approximately $6.4B was raised, 1% […]
January 23, 2018

Gene Therapy Manufacturing: An Impending Crisis or Temporary Growing Pains?

[vc_row][vc_column][vc_column_text]The Food and Drug Administration recently announced the first ever approval of a directly administered gene therapy in the United States. Spark Therapeutics one-time gene therapy […]
October 24, 2017

Monogenic Gene Therapies: Will Spark Therapeutics’ Luxturna Avoid the Fate of Glybera & Strimvelis?

[vc_row][vc_column][vc_column_text] Philadelphia-based Spark Therapeutics recently received unanimous backing from an FDA advisory panel for Luxturna™, a one-shot gene therapy treatment for biallelic RPE65-mediated inherited retinal dystrophy […]
October 16, 2017

Evotec Invests €15m in Exscientia in Latest Partnership between Big Pharma & Artificial Intelligence-Driven Drug Discovery

[vc_row][vc_column][vc_column_text] German pharmaceutical company Evotec has expanded its partnership with Scottish artificial intelligence drug design pioneers Exscientia, investing a further €15m in exchange for a minority […]
October 5, 2017

2017 Global Therapeutic IPO Market: 121% YOY Increase in Funds Raised Despite Slow Q3

[vc_row][vc_column][vc_column_text] The global therapeutic IPO market has failed to maintain the upward momentum established throughout a busy Q2 2017, with just over $1B raised by 13 […]